Arrhythmias & electrophysiology
Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial
Study context
- Population
- Patients with atrial fibrillation (AF) and CHA2DS2-VASc score > 1 who underwent percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation at least 12 months before enrollmentplanned enrolment
- Participants
- 960 patients
- Planned comparison
- NOAC monotherapy vs NOAC plus clopidogrel
- Primary endpoint
- NACE:
- All-cause death
- MI
- Stent thrombosis
- Stroke
- Systemic embolism
- Major or clinically relevant non-major bleeding by ISTH criteria
- Follow-up
- 1 year after randomization
Methodological detailsdesign and rationale, multicentre, prospective, open-label, non-inferiority, Hypothesis: NOAC monotherapy non-inferior to NOAC plus clopidogrel for net adverse clinical event (NACE)
- Design and rationale
- Multicentre
- Prospective
- Open-label
- Non-inferiority
- Hypothesis: NOAC monotherapy non-inferior to NOAC plus clopidogrel for NACE
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial. Am Heart J. Published 23 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →